List view / Grid view
24 May 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African…
23 May 2012 | By Boehringer Ingelheim
1 Mission 1 Million announces its plans to support ongoing work in atrial fibrillation...
22 May 2012 | By Boehringer Ingelheim
Comprehensive Phase III UniTinA-asthma™ program ongoing...
22 May 2012 | By Boehringer Ingelheim
1 Mission 1 Million launches petition and unique fundraising platform...
21 May 2012 | By Boehringer Ingelheim
Olodaterol significantly improved lung function (FEV 1) for at least 24 hours compared to placebo...
14 May 2012 | By University of Dundee
The consortium includes six companies & will provide core support of £14.4 million...
29 April 2012 | By Boehringer Ingelheim
New data on TWYNSTA®...
18 April 2012 | By Boehringer Ingelheim
1 Mission 1 Million announces plans to launch an exciting new phase of the initiative...
18 April 2012 | By Boehringer Ingelheim
A new analysis of the 18,113 patient...
7 March 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto™ (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.
2 March 2012 | By Boehringer Ingelheim
The European PCV2 Research Award funds research projects related to PCV2 infection and associated diseases...
29 February 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical development & manufacturing capabilities...
21 February 2012 | By Boehringer Ingelheim
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life...
3 February 2012 | By Boehringer Ingelheim
Research collaboration agreement to develop new insights into the causes of diabetes...
30 January 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who…
